Our study is different from those studiesas we (1) also included LGG and IDH-mutated HGG subgroups,not only; (2) used methylomic classification to obtain a sharp subgroup definition before proteomic analysis;(3) included factors potentially impacting protein expression levels,such as age, sex, treatments (chemotherapy, radiotherapy, steroids),and epilepsy as confounding factors in the model; and (4) includedthe use of “non-neoplastic protein markers” (HG2A, PTPRC,and SEPT3), primarily associated with tumor-associated immune cellsand neurons, to estimate their proportions in the tumor samples. Here, PTPRC is linked to epilepsy.